Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | COVID-19 impact on AML: German perspective

Marion Subklewe • 31 Aug 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, discusses the impact of the COVID-19 on the treatment and management of patients with acute myeloid leukemia (AML) in Germany. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Marion Subklewe

1:43
CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment
Marion Subklewe • 9 Dec 2023
1:04
MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial
Marion Subklewe • 9 Dec 2023
1:42
Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML
Marion Subklewe • 9 Dec 2023
2:33
Novel immunotherapies in AML and insights into the future of the treatment landscape
Marion Subklewe • 9 Dec 2023

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals